These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25030301)

  • 1. Intracellular delivery of tumor antigenic peptides in biodegradable-polymer adjuvant for enhancing cancer immunotherapy.
    Li H; Ma W
    Curr Med Chem; 2014; 21(21):2357-66. PubMed ID: 25030301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
    Wang HY; Wang RF
    Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
    Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
    Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide-based vaccines for cancer immunotherapy.
    Brinkman JA; Fausch SC; Weber JS; Kast WM
    Expert Opin Biol Ther; 2004 Feb; 4(2):181-98. PubMed ID: 14998777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized peptide vaccine for treatment of advanced cancer.
    Sasada T; Yamada A; Noguchi M; Itoh K
    Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
    J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
    Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
    Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
    Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
    Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-Based Treatment: A Promising Cancer Therapy.
    Xiao YF; Jie MM; Li BS; Hu CJ; Xie R; Tang B; Yang SM
    J Immunol Res; 2015; 2015():761820. PubMed ID: 26568964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Development of Immunomodulatory Antigen Delivery Systems Based on Peptide/PEG-PLA Conjugate for Tuning Immunity.
    Coumes F; Huang CY; Huang CH; Coudane J; Domurado D; Li S; Darcos V; Huang MH
    Biomacromolecules; 2015 Nov; 16(11):3666-73. PubMed ID: 26473322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of peptide-based tumor vaccines.
    Meng WS; Butterfield LH
    Pharm Res; 2002 Jul; 19(7):926-32. PubMed ID: 12180543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific immunotherapy of cancer in elderly patients.
    Matzku S; Zöller M
    Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines in the treatment of cancer.
    Baltz JK
    Am J Health Syst Pharm; 1995 Nov; 52(22):2574-85; quiz 2594-5. PubMed ID: 8590245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
    Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
    J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.